Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1225-1229

  Mitteldorf, C ^a,d   Bertsch, H P ^a   Baumgart, M ^b   Haase, D ^a   Wulf, G ^a   Schon M P ^a   Rosenwald, A ^c   Neumann, C ^a   Kaune, K M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Klinikum Hildesheim GmbH   (Germany)

Author keywords

allogenic bone marrow transplantation; blastic plasmacytoid dendritic cell neoplasm; CD4+CD56+; CD56 negative; chemotherapy; loss 11q23

Indexed keywords

BUSULFAN; CARBOPLATIN; CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; PREDNISOLONE; VINCRISTINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER TISSUE; CASE REPORT; CHROMOSOME 11Q; FLUORESCENCE IN SITU HYBRIDIZATION; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONOSOMY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SKIN TUMOR; TUMOR CELL; TUMOR REGRESSION;

ADULT; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHROMOSOMES, HUMAN, PAIR 11; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DOXORUBICIN; ETOPOSIDE; FATAL OUTCOME; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM RECURRENCE, LOCAL; PREDNISOLONE; SKIN; SKIN NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 80053016578     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03922.x     Document Type: Article

References (22)

1. Jacob MC, Chaperot L, Mossuz P,. CD4+CD56+ linage negative malignancies: a new entity developed from malignant early plasmacytoid dentritic cells. Haematologica 2003; 88: 941-955.
2. Hallermann C, Middel P, Griesinger F, Gunawan B, Bertsch HP, Neumann C,. CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dentritic cells. Eur J Dermatol 2004; 14: 317-322.
3. Herling M, Jones D,. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007; 127: 687-700.
4. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Oncol 2005; 123: 662-675.
5. Feuillard J, Jacob M-C, Valensi F, et al. Clinical and biological features of CD4(+)CD56(+) malignancies. Blood 2002; 99: 1556-1563.
6. Petrella T, Teitell MA, Spiekermann C, Meijers CJ, Franck F, Enache I,. A CD56-negative case of blastic natural killer-cell lymphoma (agranular CD4+/CD56+ haematodermic neoplasm). Br J Dermatol 2004; 150: 174-176.
7. Kawai K,. CD56-negative blastic natural killer cell lymphoma (agranular CD4(+)/CD56(+) haematodermic neoplasm)? Br J Dermatol 2005; 152: 369-370.
8. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 2009; 145: 624-636.
9. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34: 75-87.
10. Roesler J, Srivatsan E, Moatamed F, Peters J, Livingston EH,. Tumor suppressor activity of neural cell adhesion molecule in colon carcinoma. Am J Surg 1997; 174: 251-257.
11. Chang H, Samiee S, Yi QL,. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006; 47: 43-47.
12. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 123: 213-219.
13. González MB, Hernández JM, García JL, et al. The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma. Haematologica 2004; 89: 1213-1218.
14. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmocytoid dendritic cells. Blood 2001; 97: 3210-3217.
15. Kaune KM, Baumgart M, Bertsch HP, et al. Solitary cutaneous nodule of blastic plasmacytoid dendritic cell neoplasm progressing to overt leukemia cutis after chemotherapy: immunohistology and FISH analysis confirmed the diagnosis. Am J Dermatopathol 2009; 31: 695-701.
16. Leroux D, Mugneret F, Callanan M, et al. on behalf of Groupe Francais de Cytogénétique Hématologique (GFCH). CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogénétique Hématologique. Blood 2002; 99: 4154-4159.
17. Huerta S, Srivatsan ES, Venkatesan N, et al. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery 2001; 130: 834-841.
18. Austen B, Skowronska A, Baker C, et al. Mutation status of residual ATM allele is an important determinant of the cellular response to chemotherapy and survival with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448-5457.
19. Tsiftsoglou AS, Pappas IS, Vizirianakis IS,. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther 2003; 100: 257-290.
20. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A,. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 2009; 69: 6987-6994.
21. Kaneno R, Shurin GV, Tourkova IL, Shurin MR,. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009; 10: 58.
22. Assaf C, Gellrich S, Whittaker S, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007; 60: 981-989.